676 – High Baseline Prevalence and Suboptimal Control of Hypertension in the REPRIEVE Trial
Background Hypertension is one of the most common comorbidities among people living with HIV (PLHIV), and a major contributor to cardiovascular disease (CVD) in REPRIEVE, highlighting its clinical importance. Although hypertension has been described in PLHIV, its prevalence and control in a large global primary cardiovascular prevention population has not been well characterized in PLHIV.…